Aldeyra Therapeutics to Host 2020 Research & Development Day
February 11 2020 - 8:00AM
Business Wire
Live Webcast Scheduled to Begin at Noon ET
Monday, February 24, 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a
biotechnology company devoted to developing and commercializing
next-generation medicines to improve the lives of patients with
immune-mediated diseases, today announced that it will host a
Research & Development Day on Monday, February 24, 2020, to
provide an update on current late-stage clinical development
programs.
The event will include presentations from members of the Aldeyra
executive team and Paul Karpecki, O.D., FAAO. Dr. Karpecki is
Clinical Director, Corneal Services and Advanced Ocular Surface
Disease at Kentucky Eye Institute and a clinician for Gaddie Eye
Centers. He also is an Associate Professor at the Kentucky College
of Optometry and the Medical Director for Keplr Vision and the Dry
Eye Institutes of Kentucky and Indiana.
The presentations will focus on the company’s development plans
and market opportunities for its novel product candidates in dry
eye disease, allergic conjunctivitis, and proliferative
vitreoretinopathy.
The presentations are scheduled to begin at Noon (ET) Monday,
February 24, 2020, in New York, NY.
A live audio webcast of the presentation and a slide deck will
be available via the company's Investor Relations website at
https://ir.aldeyra.com/. Following the live webcast, an archived
version will be available on the website for 90 days.
About Aldeyra Therapeutics Aldeyra Therapeutics is a
biotechnology company devoted to developing and commercializing
next-generation medicines to improve the lives of patients with
immune-mediated diseases. Aldeyra's lead investigational drug
product candidates are potential first-in-class treatments in
development for dry eye disease, allergic conjunctivitis,
proliferative vitreoretinopathy, and Sj�gren-Larsson Syndrome. The
company is also developing other product candidates for retinal and
systemic inflammatory diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200211005323/en/
Corporate Contact: David McMullin Aldeyra Therapeutics,
Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon
Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024